Revenue: As of FY2025 Q1, the actual value is USD 68.16 M, missing the estimate of USD 68.39 M.EPS: As of FY2025 Q1, the actual value is USD -0.77.EBIT: As of FY2025 Q1, the actual value is USD -97.88 M.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $64.959 million for the three months ended March 31, 2025, compared to $47.845 million for the same period in 2024, representing a 36% increase.</li><li>Other Revenue: $3.205 million for the three months ended March 31, 2025, compared to $2.945 million for the same period in 2024, representing a 9% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $96.099 million for the three months ended March 31, 2025, compared to - $8.721 million for the same period in 2024.</li><li>Loss from Operations: - $23.630 million for the three months ended March 31, 2025, compared to - $17.769 million for the same period in 2024.</li><li>Total Operating Expenses: $91.794 million for the three months ended March 31, 2025, compared to $68.559 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $19.639 million for the three months ended March 31, 2025, compared to - $16.679 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $6.910 million for the three months ended March 31, 2025, compared to $2.831 million for the same period in 2024.</li><li>Net Cash Used in Financing Activities: - $31.882 million for the three months ended March 31, 2025, compared to - $4.203 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Allowance for Doubtful Accounts: Approximately $11.0 million recorded during the three months ended March 31, 2025, related to the contract asset recognized for Clover.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Dynavax Technologies Corporation plans to advance its clinical pipeline leveraging CpG 1018 adjuvant, including a Phase 1⁄2 clinical trial for shingles and additional clinical and manufacturing activities for plague, fully funded by the U.S. Department of Defense.</li><li>Non-Core Business: The company is pursuing collection of $71.3 million due from Clover, with $60.3 million payable to CEPI upon occurrence of applicable payment trigger events.</li><li>Priority: The company anticipates that its cash and cash equivalents, and short-term marketable securities as of March 31, 2025, and anticipated revenues from HEPLISAV-B will be sufficient to fund operations for at least the next 12 months.</li></ul>

Dynavax Tech | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 68.16 M